华森制药(002907) - 2024 Q4 - 年度业绩预告

Financial Projections - The estimated net profit for 2024 is projected to be between 56 million and 81 million CNY, representing an increase of 71.26% to 147.71% compared to the previous year's profit of 32.7 million CNY[3] - The net profit after deducting non-recurring gains and losses is expected to be between 40 million and 57 million CNY, reflecting an increase of 92.88% to 174.86% from last year's figure of 20.7 million CNY[3] - Basic earnings per share are projected to be between 0.1341 CNY and 0.1940 CNY, compared to 0.0783 CNY in the previous year[3] Revenue Drivers - The increase in profit is primarily attributed to a rise in main business revenue, particularly from traditional Chinese medicine products, and successful bidding for certain products[6] - The company has expanded its market presence by increasing the number of provinces and cities where its products are listed following successful bidding[6] Government Support and R&D - The company received increased government subsidies, particularly for the HSN002 project under the "Chongqing Science and Technology Tackling Key Projects" program[6] - R&D expenses decreased compared to the previous year due to changes in investment phases and demand[6] Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be confirmed in the 2024 annual report[7]